Gastrointestinal Cancer

News alerts, weekly reports and conference planners

HER-2 positive	Colorectal Cancer	HER-2 positive	Colorectal Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label ASCO 2023 - 3 days (New C3) fam-trastuzumab deruxtecan-nxki Sensitive : C1 ASCO 2023 - 3d	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label ASCO 2023 - 3 days fam-trastuzumab deruxtecan-nxki Sensitive : C1 ASCO 2023 - 3 days - (New C3)
BRAF V600	Colorectal Cancer	BRAF V600	Colorectal Cancer	FORE-8394 Sensitive: C3 – Early Trials ASCO 2023 - 3 days (New C3) FORE-8394 Sensitive : C3 ASCO 2023 - 3d	FORE-8394 Sensitive: C3 – Early Trials ASCO 2023 - 3 days FORE-8394 Sensitive : C3 ASCO 2023 - 3 days - (New C3)
FGFR2-BICC1 fusion	Cholangiocarcinoma	FGFR2-BICC1 fusion	Cholangiocarcinoma	pembrolizumab + pemigatinib Sensitive: C4 – Case Studies Front Immunol - 4 days (New C4) pembrolizumab + pemigatinib Sensitive : C4 Front Immunol - 4d	pembrolizumab + pemigatinib Sensitive: C4 – Case Studies Front Immunol - 4 days pembrolizumab + pemigatinib Sensitive : C4 Front Immunol - 4 days - (New C4)
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	panitumumab Sensitive: A1 - Approval JAMA Oncol - 1 week (New C3) panitumumab Sensitive : A1 JAMA Oncol - 1wk	panitumumab Sensitive: A1 - Approval JAMA Oncol - 1 week panitumumab Sensitive : A1 JAMA Oncol - 1 week - (New C3)
IDH1 R132	Cholangiocarcinoma	IDH1 R132	Cholangiocarcinoma	ivosidenib Sensitive: A1 - Approval Servier Press Release - 2 weeks (New A1) ivosidenib Sensitive : A1 Servier Press Release - 2wk	ivosidenib Sensitive: A1 - Approval Servier Press Release - 2 weeks ivosidenib Sensitive : A1 Servier Press Release - 2 weeks - (New A1)
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	cetuximab + camrelizumab Sensitive: C3 – Early Trials Int J Cancer - 2 weeks (New C3) cetuximab + camrelizumab Sensitive : C3 Int J Cancer - 2wk	cetuximab + camrelizumab Sensitive: C3 – Early Trials Int J Cancer - 2 weeks cetuximab + camrelizumab Sensitive : C3 Int J Cancer - 2 weeks - (New C3)
FGFR2 amplification	Gastric Adenocarcinoma	FGFR2 amplification	Gastric Adenocarcinoma	nintedanib Sensitive: D – Preclinical Front Oncol - 2 weeks (New D) nintedanib Sensitive : D Front Oncol - 2wk	nintedanib Sensitive: D – Preclinical Front Oncol - 2 weeks nintedanib Sensitive : D Front Oncol - 2 weeks - (New D)
TMB-H	Pancreatic Adenocarcinoma	TMB-H	Pancreatic Adenocarcinoma	nivolumab + ipilimumab Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) nivolumab + ipilimumab Sensitive : A2 NCCN - 3wk	nivolumab + ipilimumab Sensitive: A2 - Guideline NCCN - 3 weeks nivolumab + ipilimumab Sensitive : A2 NCCN - 3 weeks - (New A2)
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	FOLFIRI Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) FOLFIRI Sensitive : A2 NCCN - 3wk	FOLFIRI Sensitive: A2 - Guideline NCCN - 3 weeks FOLFIRI Sensitive : A2 NCCN - 3 weeks - (New A2)
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	OFF Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) OFF Sensitive : A2 NCCN - 3wk	OFF Sensitive: A2 - Guideline NCCN - 3 weeks OFF Sensitive : A2 NCCN - 3 weeks - (New A2)
RAS wild-type + HER-2 positive	Colorectal Cancer	RAS wild-type + HER-2 positive	Colorectal Cancer	trastuzumab + tucatinib Sensitive: A1 - Approval Lancet Oncol - 3 weeks (New C3) trastuzumab + tucatinib Sensitive : A1 Lancet Oncol - 3wk	trastuzumab + tucatinib Sensitive: A1 - Approval Lancet Oncol - 3 weeks trastuzumab + tucatinib Sensitive : A1 Lancet Oncol - 3 weeks - (New C3)
MSI-H/dMMR	Colon Cancer	MSI-H/dMMR	Colon Cancer	pembrolizumab Sensitive: A2 - Guideline Int J Surg Case Rep - 3 weeks (New C4) pembrolizumab Sensitive : A2 Int J Surg Case Rep - 3wk	pembrolizumab Sensitive: A2 - Guideline Int J Surg Case Rep - 3 weeks pembrolizumab Sensitive : A2 Int J Surg Case Rep - 3 weeks - (New C4)
KRAS G12C	Pancreatic Adenocarcinoma	KRAS G12C	Pancreatic Adenocarcinoma	sotorasib Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) sotorasib Sensitive : A2 NCCN - 3wk	sotorasib Sensitive: A2 - Guideline NCCN - 3 weeks sotorasib Sensitive : A2 NCCN - 3 weeks - (New A2)
KRAS G12C	Pancreatic Adenocarcinoma	KRAS G12C	Pancreatic Adenocarcinoma	adagrasib Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) adagrasib Sensitive : A2 NCCN - 3wk	adagrasib Sensitive: A2 - Guideline NCCN - 3 weeks adagrasib Sensitive : A2 NCCN - 3 weeks - (New A2)
MSI-H/dMMR	Pancreatic Adenocarcinoma	MSI-H/dMMR	Pancreatic Adenocarcinoma	dostarlimab-gxly Sensitive: A2 - Guideline NCCN - 3 weeks (New A2) dostarlimab-gxly Sensitive : A2 NCCN - 3wk	dostarlimab-gxly Sensitive: A2 - Guideline NCCN - 3 weeks dostarlimab-gxly Sensitive : A2 NCCN - 3 weeks - (New A2)
TMB-H	Colorectal Cancer	TMB-H	Colorectal Cancer	Immunotherapy Sensitive: C3 – Early Trials JAMA Netw Open - 3 weeks (New C3) Immunotherapy Sensitive : C3 JAMA Netw Open - 3wk	Immunotherapy Sensitive: C3 – Early Trials JAMA Netw Open - 3 weeks Immunotherapy Sensitive : C3 JAMA Netw Open - 3 weeks - (New C3)
ARID1A mutation	Biliary Tract Cancer	ARID1A mutation	Biliary Tract Cancer	cisplatin + gemcitabine Resistant: C3 – Early Trials Cancer Res Treat - 3 weeks (New C3) cisplatin + gemcitabine Resistant : C3 Cancer Res Treat - 3wk	cisplatin + gemcitabine Resistant: C3 – Early Trials Cancer Res Treat - 3 weeks cisplatin + gemcitabine Resistant : C3 Cancer Res Treat - 3 weeks - (New C3)
PIK3CA P449T	Colorectal Cancer	PIK3CA P449T	Colorectal Cancer	ribociclib Sensitive: D – Preclinical Anticancer Res - 3 weeks (New D) ribociclib Sensitive : D Anticancer Res - 3wk	ribociclib Sensitive: D – Preclinical Anticancer Res - 3 weeks ribociclib Sensitive : D Anticancer Res - 3 weeks - (New D)
MSI-H/dMMR	Small Intestinal Carcinoma	MSI-H/dMMR	Small Intestinal Carcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Adenocarcinoma	No biomarker	Esophageal Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Gastric Adenocarcinoma	No biomarker	Gastric Adenocarcinoma	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1	cisplatin + docetaxel + 5-fluorouracil Sensitive: A1 - Approval cisplatin + docetaxel + 5-fluorouracil Sensitive : A1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1
BRCA2 mutation	Pancreatic Cancer	BRCA2 mutation	Pancreatic Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : A1	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : A1
BRCA1 mutation	Pancreatic Cancer	BRCA1 mutation	Pancreatic Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
FGFR2 rearrangement	Cholangiocarcinoma	FGFR2 rearrangement	Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1
FGFR2 fusion	Cholangiocarcinoma	FGFR2 fusion	Cholangiocarcinoma	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1	infigratinib Sensitive: A1 - Approval infigratinib Sensitive : A1
IDH1 mutation	Cholangiocarcinoma	IDH1 mutation	Cholangiocarcinoma	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1	ivosidenib Sensitive: A1 - Approval ivosidenib Sensitive : A1
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	TPF Sensitive: A1 - Approval TPF Sensitive : A1	TPF Sensitive: A1 - Approval TPF Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	TPF Sensitive: A1 - Approval TPF Sensitive : A1	TPF Sensitive: A1 - Approval TPF Sensitive : A1
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	pembrolizumab + trastuzumab Sensitive: A1 - Approval pembrolizumab + trastuzumab Sensitive : A1	pembrolizumab + trastuzumab Sensitive: A1 - Approval pembrolizumab + trastuzumab Sensitive : A1
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + encorafenib + binimetinib Sensitive: A1 - Approval cetuximab + encorafenib + binimetinib Sensitive : A1	cetuximab + encorafenib + binimetinib Sensitive: A1 - Approval cetuximab + encorafenib + binimetinib Sensitive : A1
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + encorafenib Sensitive: A1 - Approval cetuximab + encorafenib Sensitive : A1	cetuximab + encorafenib Sensitive: A1 - Approval cetuximab + encorafenib Sensitive : A1
No biomarker	Colon Cancer	No biomarker	Colon Cancer	capecitabine Sensitive: A1 - Approval capecitabine Sensitive : A1	capecitabine Sensitive: A1 - Approval capecitabine Sensitive : A1
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	FOLFIRI Sensitive: A1 - Approval FOLFIRI Sensitive : A1	FOLFIRI Sensitive: A1 - Approval FOLFIRI Sensitive : A1
No biomarker	Colon Cancer	No biomarker	Colon Cancer	5-fluorouracil + irinotecan Sensitive: A1 - Approval 5-fluorouracil + irinotecan Sensitive : A1	5-fluorouracil + irinotecan Sensitive: A1 - Approval 5-fluorouracil + irinotecan Sensitive : A1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1
HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1

Gastrointestinal Cancer

Associations(3234)

Associations
(3234)